方法对比
并排查看您选择的方法；存在差异的行会高亮显示。
| 贝叶斯III期临床试验× | III期临床试验× | |
|---|---|---|
| 领域 | 流行病学 | 流行病学 |
| 方法族 | Process / pipeline | Process / pipeline |
| 起源年份≠ | 1990s–2000s (widespread application) | 1962 (Kefauver-Harris Amendment formalised phased drug development) |
| 提出者≠ | Donald A. Berry; David J. Spiegelhalter (formalization in clinical context) | FDA regulatory framework / ICH guidelines |
| 类型≠ | Confirmatory randomized controlled trial with Bayesian inference | Confirmatory randomised controlled trial |
| 开创性文献≠ | Spiegelhalter, D. J., Abrams, K. R., & Myles, J. P. (2004). Bayesian Approaches to Clinical Trials and Health-Care Evaluation. Wiley. ISBN: 978-0471499756 | Friedman, L. M., Furberg, C. D., DeMets, D. L., Reboussin, D. M., & Granger, C. B. (2015). Fundamentals of Clinical Trials (5th ed.). Springer. ISBN: 978-3319185385 |
| 别名 | Bayesian confirmatory trial, Bayesian RCT Phase III, Bayesian pivotal trial, BayesCT | Phase 3 trial, confirmatory trial, pivotal trial, Phase III RCT |
| 相关≠ | 5 | 6 |
| 摘要≠ | A Bayesian Phase III clinical trial is a large-scale, confirmatory randomized controlled trial that uses Bayesian statistical inference rather than conventional frequentist hypothesis testing to evaluate whether an experimental treatment meets pre-defined efficacy and safety thresholds. By combining prior evidence with accumulating trial data, it quantifies the probability that the treatment effect exceeds a clinically meaningful threshold, enabling more transparent decision-making under uncertainty. | A Phase III clinical trial is a large-scale, confirmatory randomised controlled trial designed to establish the efficacy and safety of an intervention in the target patient population before regulatory submission. It builds on the signal identified in Phase II, tests the intervention at its proposed dose under controlled conditions, and provides the primary evidence base for marketing authorisation or guideline adoption. |
| ScholarGate数据集 ↗ |
|
|